- ►onlinejacc.org [PDF] E Erdmann, JA Dormandy, B Charbonnel, M … - Journal of the American College of Cardiology, 2007 - Elsevier This analysis from the PROactive (PROspective pioglitAzone Clinical Trial In
macroVascular Events) study assesses the effects of pioglitazone on mortality
and macrovascular morbidity in patients with type 2 diabetes and a previous ... Cited by 81 - Related articles - BL Direct - All 13 versions
- ►diabetesjournals.org SE Inzucchi, FA Masoudi, Y Wang, M … - Diabetes Care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—We conducted a retrospective cohort study of
24,953 Medicare beneficiaries with diabetes discharged after hospitalization
with AMI between April 1998 and March 1999 or July 2000 and June 2001. The ... Cited by 53 - Related articles - BL Direct - All 5 versions
M Lindberg, A Astrup - Obesity Reviews, 2007 - interscience.wiley.com Glitazones have been introduced as second-step medication for type 2 diabetics,
and today rosiglitazone and pioglitazone are blockbuster drugs. However,
glitazones may have important adverse effects that outweight their ... Cited by 9 - Related articles - BL Direct - All 5 versions
- ►sherbornegibbs.com [PDF] J Bottomley, AJ Palmer, R Williams, J … - The British Journal of Diabetes & Vascular Disease, 2006 - dvd.sagepub.com Page 1. http://dvd.sagepub.com The British Journal of Diabetes & Vascular Disease
DOI: 10.1177/14746514060060020401 2006; 6; 63 British ... Cited by 5 - Related articles - All 9 versions
O Barthelemy, C Le Feuvre, J Timsit - Arquivos Brasileiros de Endocrinologia & Metabologia, 2007 - SciELO Brasil The prevalence of diabetes mellitus is fairly increasing, especially in the
developing countries. Diabetes is a major cardiovascular risk factor; it often
leads to severe cardiovascular complications, and coronary artery disease ... Cited by 5 - Related articles - Cached - All 3 versions
OE Schmitz, B Brock, J Rungby, S Madsbad - UGESKRIFT FOR LAEGER, 2006 - ugeskriftet.dk I United Kingdom Prospective Diabetets Study (UKPDS) blev der hos nykonstaterede
type 2-diabetikere påvist, at der efter i gennemsnit ti års observationstid
med en reduceret glykeret hæmoglobin (HbA1c) på 0,9% ikke fandtes en ... Cited by 3 - Related articles - View as HTML - BL Direct - All 3 versions
[CITATION] PPARγ-agonister–antidiabetika med gunstig effekt på kardiovaskulær risiko?
PLPD Stamm, KWPD Kelley, ARPD … - Advances in Pharmacy, 2005 - pt.wkhealth.com Most patients with type 2 diabetes mellitus will die from cardiovascular disease
(CVD). Diabetic patients experience accelerated development of CVD and lower
survival rates after CVD events. The following critical review presents ... Cited by 1 - Related articles
- ►uwyo.edu [PDF] EJ Miller, RR Russell, J Li, LH Young - Drug Discovery Today: Disease Mechanisms, 2005 - Elsevier Despite progress in cardiovascular disease treatment with anti-thrombotic
therapy, statins and neurohormonal blockade, myocardial-based approaches can
provide additional opportunities for unique therapeutic advances. The ... Cited by 1 - Related articles - All 2 versions
J Bottomley, AJ Palmer, R Williams, J … - canadiancpd.medscape.com Economic value of medicines, medical devices and other technologies is an
increasingly important consideration in healthcare management. Conducting high
quality economic analyses alongside randomized controlled clinical trials ...
